المؤلفون: Gaffney, Christopher D., Katims, Andrew, D'Souza, Neeta, Bjurlin, Marc A., Matulewicz, Richard S.

المساهمون: National Cancer Institute

المصدر: European Urology Focus ; volume 9, issue 4, page 575-578 ; ISSN 2405-4569

مصطلحات موضوعية: Urology

الإتاحة: https://doi.org/10.1016/j.euf.2023.03.017Test
https://api.elsevier.com/content/article/PII:S240545692300086X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S240545692300086X?httpAccept=text/plainTest

المؤلفون: Lenis, Andrew T, Ravichandran, Vignesh, Brown, Samantha, Alam, Syed M, Katims, Andrew, Truong, Hong, Reisz, Peter A, MD, Vasselman, Samantha, Nweji, Barbara, Autio, Karen A, Morris, Michael J, Slovin, Susan F, Rathkopf, Dana, Danila, Daniel, Scher, Howard I, Woo, Sungmin, Vargas, Hebert Alberto, Laudone, Vincent P, Ehdaie, Behfar, Reuter, Victor, Arcila, Maria, Berger, Michael F, Viale, Agnes, Schultz, Nikolaus, Gopalan, Anuradha, Donoghue, Mark T A, Ostrovnaya, Irina, Stopsack, Konrad H, Solit, David B, Abida, Wassim

المصدر: Department of Medicine

مصطلحات موضوعية: Department of Medicine, Medicine and Health Sciences

الوصف: PURPOSE: Patients with microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, and response to immune checkpoint blockade (ICB) in patients with MSI-H/dMMR and TMB-H prostate cancers without MSI (TMB-H/MSS). METHODS: We sequenced 3,244 tumors from 2,257 prostate cancer patients. MSI-H/dMMR prostate cancer was defined as MSIsensor score ≥10 or MSIsensor score ≥3 and≥10 mutations/megabase. PSA50 and RECIST responses were assigned. Overall survival (OS) and radiographic progression-free survival (rPFS) were compared using log rank test. RESULTS: 63 (2.8%) men had MSI-H/dMMR and 33 (1.5%) had TMB-H/MSS prostate cancers. Patients with MSI-H/dMMR and TMB-H/MSS tumors more commonly presented with grade group 5 and metastatic disease at diagnosis. MSI-H/dMMR tumors had higher TMB, indel and neoantigen burden compared with TMB-H/MSS. 27 patients with MSI-H/dMMR and 8 patients with TMB-H/MSS tumors received ICB, none of whom harbored POLE mutations. 45% of MSI-H/dMMR patients had a RECIST response and 65% had a PSA50 response. No TMB-H/MSS patient had a RECIST response and 50% had a PSA50 response. rPFS tended to be longer in MSI-H/dMMR patients than in TMB-H/MSS patients who received immunotherapy. Pronounced differences in genomics, TMB or MSIsensor score were not detected between MSI-H/dMMR responders and non-responders. CONCLUSIONS: MSI-H/dMMR prostate cancers have greater TMB, indel and neoantigen burden compared with TMB-H/MSS prostate cancers, and these differences may contribute to more profound and durable responses to ICB.

العلاقة: https://scholarlyworks.lvhn.org/medicine/6779Test; https://pubmed.ncbi.nlm.nih.gov/38949888Test/

الإتاحة: https://scholarlyworks.lvhn.org/medicine/6779Test
https://pubmed.ncbi.nlm.nih.gov/38949888Test/

المؤلفون: Lenis, Andrew T, Whiting, Karissa, Ravichandran, Vignesh, Tallman, Jacob E, Alam, Syed M, Chu, Carissa E, Jesus Escano, Manual De, Bochner, Emily, Katims, Andrew, Reisz, Peter A, Truong, Hong, Clinton, Timothy N, Telis, Leon, Dason, Shawn, McPherson, Victor, Teo, Min Yuen, Funt, Samuel, Aggen, David, Goh, Alvin C, Donahue, Timothy F, Cha, Eugene K, Donat, S Machele, Herr, Harry W, Dalbagni, Guido, Schultz, Nikolaus, Berger, Michael F, Bajorin, Dean F, Rosenberg, Jonathan E, Bochner, Bernard H, Ostrovnaya, Irina, Al-Ahmadie, Hikmat, Solit, David B, Iyer, Gopa, Pietzak, Eugene J

المصدر: JCO Precis Oncol ; ISSN:2473-4284 ; Volume:8

الوصف: Patients with residual invasive bladder cancer after neoadjuvant chemotherapy (NAC) and radical cystectomy have a poor prognosis. Data on adjuvant therapy for these patients are conflicting. We sought to evaluate the natural history and genomic landscape of chemotherapy-resistant bladder cancer to inform patient management and clinical trials.

العلاقة: https://doi.org/10.1200/PO.23.00274Test; https://pubmed.ncbi.nlm.nih.gov/38691813Test

الإتاحة: https://doi.org/10.1200/PO.23.00274Test
https://pubmed.ncbi.nlm.nih.gov/38691813Test

المؤلفون: Yu, Alice, Hensley, Patrick J., Huelster, Heather L., Martin, Austin, Pham, Jonathan, Pallauf, Maximilian, Katims, Andrew, Potrezke, Aaron, Raman, Jay D., Singla, Nirmish, Margulis, Vitaly, Coleman, Jonathan, Matin, Surena F., Spiess, Philippe E.

المصدر: Journal of Urology ; volume 211, issue 5S ; ISSN 0022-5347 1527-3792

الإتاحة: https://doi.org/10.1097/01.ju.0001009556.54476.eb.08Test

المؤلفون: Katims, Andrew B., Tin, Amy L., Hensley, Patrick, Li, Roger, Margulis, Vitaly, Matin, Surena, Pallauf, Maximilian, Pham, Jonathan, Raman, Jay D., Singla, Nirmish, Spiess, Philippe E., Coleman, Jonathan

المصدر: Journal of Urology ; volume 211, issue 5S ; ISSN 0022-5347 1527-3792

الإتاحة: https://doi.org/10.1097/01.ju.0001008700.92603.b1.02Test

المؤلفون: Alam, Muneeb, Katims, Andrew B., Tallman, Jacob E., Yip, Wesley, Pietzak, Eugene J., Al-Ahmadie, Hikmat, Bochner, Bernard H., Kim, Kwanghee, Solit, David B., Coleman, Jonathan A.

المصدر: Journal of Urology ; volume 211, issue 5S ; ISSN 0022-5347 1527-3792

الإتاحة: https://doi.org/10.1097/01.ju.0001008568.76803.f1.02Test

المؤلفون: Katims, Andrew B., Lavery, Jessica A., Ostrovnaya, Irina, Bochner, Bernard H., Dalbagni, Guido, Donahue, Timothy A., Donat, S. Machele, Herr, Harry W., Pietzak, Eugene J., Al-Ahmadie, Hikmat, Solit, David B., Coleman, Jonathan A.

المصدر: Urologic Oncology: Seminars and Original Investigations ; volume 42, page S21 ; ISSN 1078-1439

مصطلحات موضوعية: Urology, Oncology

الإتاحة: https://doi.org/10.1016/j.urolonc.2024.01.086Test
https://api.elsevier.com/content/article/PII:S1078143924001029?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1078143924001029?httpAccept=text/plainTest

المؤلفون: Katims, Andrew B., D'Souza, Neeta, Escaño, Manuel Ramón De Jesus, Gokturk, Gamze, Basar, Merve, Solit, David B., Iyer, Gopa, Bochner, Bernard H., Goh, Alvin, Donahue, Timothy A., Sarungbam, Judy, Lin, Oscar, Al-Ahmadie, Hikmat, Pietzak, Eugene J., Farha, Mark

المصدر: Urologic Oncology: Seminars and Original Investigations ; volume 42, page S46 ; ISSN 1078-1439

مصطلحات موضوعية: Urology, Oncology

الإتاحة: https://doi.org/10.1016/j.urolonc.2024.01.145Test
https://api.elsevier.com/content/article/PII:S1078143924001613?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1078143924001613?httpAccept=text/plainTest

المؤلفون: Katims, Andrew B., Tallman, Jacob, Vertosick, Emily, Porwal, Shaun, Dalbagni, Guido, Cha, Eugene K., Smith, Robert, Benfante, Nicole, Herr, Harry W.

المصدر: JAMA Oncology ; volume 10, issue 4, page 522 ; ISSN 2374-2437

الوصف: Importance With the ongoing bacillus Calmette-Guèrin (BCG) shortage, alternate therapeutic options for patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are needed. Objective To report the 5-year outcomes of a cohort from a prospective phase 2 trial of patients with high-risk NMIBC who underwent 12 instillations of induction BCG without maintenance. Design, Setting, and Participants Between November 2015 and June 2018, patients at Memorial Sloan Kettering Cancer Center with primary or recurrent NMIBC (high-grade Ta, T1 tumors, with or without carcinoma in situ) were prospectively enrolled to receive 2 induction courses (12 intravesical instillations) of BCG without maintenance therapy. The analysis itself took place on July 28, 2023. Main Outcomes and Measures Recurrence-free survival (RFS) and cancer-specific survival (CSS) was assessed by landmark analysis at 7.5 months. Recurrence was defined as pathologic high-grade disease. Results Among 81 patients (65 men [84%] and 12 women [16%] with a median [IQR] age of 72 [64-77] years) who consented to participate in the study, 75 remained evaluable for long-term follow-up analysis. Twenty-one patients experienced high-grade recurrence, yielding a 5-year RFS rate of 69% (95% CI, 58%-81%), with a median (IQR) follow-up of 4.4 (3.8-5.3) years for patients without recurrence. Three patients died of bladder cancer, corresponding to a CSS rate of 97% (95% CI, 93%-100%) with a median (IQR) follow-up of 4.9 (4.2-5.7) years for survivors. Using 2 induction courses reduced the amount of BCG per patient from 27 vials to 12 vials. Conclusion and Relevance Twelve induction instillations of BCG without maintenance for patients with high-risk NMIBC reduced the number of vials needed per patient while providing acceptable oncologic outcomes. Given the ongoing BCG shortage, this modified regimen may provide a suitable alternative in this setting.

الإتاحة: https://doi.org/10.1001/jamaoncol.2023.6804Test
https://jamanetwork.com/journals/jamaoncology/articlepdf/2815004/jamaoncology_katims_2024_br_230024_1712704320.31735.pdfTest

المؤلفون: Bieber, Christine, Katims, Andrew, Ranti, Daniel, Sfakianos, John P., Amend, Gregory

المصدر: Urology Case Reports ; volume 45, page 102236 ; ISSN 2214-4420

مصطلحات موضوعية: Urology

الإتاحة: https://doi.org/10.1016/j.eucr.2022.102236Test
https://api.elsevier.com/content/article/PII:S2214442022002480?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2214442022002480?httpAccept=text/plainTest